Picture loading failed.

Anti-IFNA1 therapeutic antibody (Pre-made Rontalizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Rontalizumab is a humanized monoclonal antibody being developed by Genentech. As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.、

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-494-1mg 1mg 3090
GMP-Bios-ab-494-10mg 10mg 21890
GMP-Bios-ab-494-100mg 100mg 148000
GMP-Bios-ab-494-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IFNA1 therapeutic antibody (Pre-made Rontalizumab biosimilar,Whole mAb)
INN Name Rontalizumab
TargetIFNA1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesChugai Pharmaceutical;Genentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSystemic lupus erythematosus
Development Techna